Overview

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Agennix
Treatments:
Satraplatin